Macerich Company (The) Common Stock vs Tango Therapeutics Inc. — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.39B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Macerich Company (The) Common Stock is the larger of the two by market cap, and Macerich Company (The) Common Stock pays a 3.02% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Tango Therapeutics Inc. for 0 Days on average.
| MAC | TNGX | |
|---|---|---|
Market Cap | $6.39B | $3.75B |
Volume | 2,684,151 | 9,619,106 |
Sector | Real Estate | Health |
52-Week High | $26.51 | $32.90 |
52-Week Low | $16.20 | $7.50 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.07B | $2.77B |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →